Hillevax Inc
HLVX2.060USD
+0.020+0.98%
Horário de mercado （ET）Cotações atrasadas em 15 min
103.21MValor de mercado
PerdaP/L TTM
Mais detalhes de Hillevax Inc Empresa
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Informações da empresa
Código da empresaHLVX
Nome da EmpresaHillevax Inc
Data de listagemApr 29, 2022
CEODr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Número de funcionários14
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 29
Endereço321 Harrison Ave, Suite 500
CidadeBOSTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02118
Telefone16172135054
Sitehttps://www.hillevax.com/
Código da empresaHLVX
Data de listagemApr 29, 2022
CEODr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
876.86K
+11.51%
Mr. Jaime Sepulveda, M.D.
Mr. Jaime Sepulveda, M.D.
Independent Director
Independent Director
59.22K
+40.93%
Ms. Jeryl Hilleman
Ms. Jeryl Hilleman
Independent Director
Independent Director
59.22K
+40.93%
Mr. Shane Maltbie, CPA
Mr. Shane Maltbie, CPA
Chief Financial Officer
Chief Financial Officer
38.30K
-52.06%
Dr. Gary Dubin, M.D.
Dr. Gary Dubin, M.D.
Independent Director
Independent Director
17.20K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Lead Independent Director
Lead Independent Director
17.20K
--
Dr. Nanette Cocero, Ph.D.
Dr. Nanette Cocero, Ph.D.
Independent Director
Independent Director
17.20K
--
Dr. Shelley Chu, M.D., Ph.D.
Dr. Shelley Chu, M.D., Ph.D.
Independent Director
Independent Director
17.20K
--
Dr. Aditya Kohli, Ph.D.
Dr. Aditya Kohli, Ph.D.
Director
Director
--
--
Dr. Julie Louise Gerberding, M.D.
Dr. Julie Louise Gerberding, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
876.86K
+11.51%
Mr. Jaime Sepulveda, M.D.
Mr. Jaime Sepulveda, M.D.
Independent Director
Independent Director
59.22K
+40.93%
Ms. Jeryl Hilleman
Ms. Jeryl Hilleman
Independent Director
Independent Director
59.22K
+40.93%
Mr. Shane Maltbie, CPA
Mr. Shane Maltbie, CPA
Chief Financial Officer
Chief Financial Officer
38.30K
-52.06%
Dr. Gary Dubin, M.D.
Dr. Gary Dubin, M.D.
Independent Director
Independent Director
17.20K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Lead Independent Director
Lead Independent Director
17.20K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 29 de jul
Atualizado em: ter, 29 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Frazier Life Sciences Management, L.P.
21.17%
Takeda Pharmaceutical Co Ltd
13.41%
Tang Capital Management, LLC
9.81%
EcoR1 Capital, LLC
5.77%
Lightspeed Venture Partners
4.59%
Other
45.24%
Investidores
Investidores
Proporção
Frazier Life Sciences Management, L.P.
21.17%
Takeda Pharmaceutical Co Ltd
13.41%
Tang Capital Management, LLC
9.81%
EcoR1 Capital, LLC
5.77%
Lightspeed Venture Partners
4.59%
Other
45.24%
Tipos de investidores
Investidores
Proporção
Private Equity
22.82%
Hedge Fund
16.80%
Investment Advisor/Hedge Fund
15.22%
Corporation
13.41%
Investment Advisor
11.56%
Venture Capital
9.11%
Individual Investor
3.71%
Research Firm
1.02%
Bank and Trust
0.08%
Other
6.27%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
224
44.13M
88.00%
-14.24M
2025Q1
229
46.31M
92.39%
-14.77M
2024Q4
226
47.12M
94.62%
-13.67M
2024Q3
218
46.00M
92.53%
-13.52M
2024Q2
202
49.77M
100.23%
-2.02M
2024Q1
182
48.47M
97.79%
-558.66K
2023Q4
166
46.57M
96.99%
+4.81M
2023Q3
161
39.77M
86.30%
+8.72M
2023Q2
146
30.99M
80.52%
+1.24M
2023Q1
140
32.25M
85.25%
+3.76M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Frazier Life Sciences Management, L.P.
10.62M
21.17%
--
--
Mar 31, 2025
Takeda Pharmaceutical Co Ltd
6.72M
13.41%
--
--
Mar 31, 2025
Tang Capital Management, LLC
4.92M
9.81%
--
--
May 02, 2025
Lightspeed Venture Partners
2.30M
4.59%
-37.51K
-1.60%
Mar 31, 2025
Franklin Advisers, Inc.
1.95M
3.9%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.92M
3.82%
-70.63K
-3.56%
Mar 31, 2025
Deerfield Management Company, L.P.
1.88M
3.75%
--
--
Mar 31, 2025
Abingworth Management Limited
1.84M
3.67%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.59M
3.16%
-20.50K
-1.28%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Global X Russell 2000 ETF
0%
Avantis Responsible US Equity ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporção0%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0%
Fidelity MSCI Health Care Index ETF
Proporção0%
Fidelity Nasdaq Composite Index ETF
Proporção0%
Global X Russell 2000 Covered Call ETF
Proporção0%
Global X Russell 2000 ETF
Proporção0%
Avantis Responsible US Equity ETF
Proporção0%
iShares Russell 2000 Value ETF
Proporção0%
ProShares Ultra Nasdaq Biotechnology
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
